Skip to main content
Frau mit Insulinpumpe am Oberarm
Icon stack
Chronic kidney disease

Improving early chronic kidney disease detection via increasing rates of urine albumin-to-creatinine (UACR) testing in type 2 diabetes patients

Icon cube

Offering
Cohort Statistics

Icon clock

Data frequency
Once delivered

Icon calendar

Duration
6 month

Icon disease

Disease
CKD

Icon building

Client
Pharma research

Icon chart

Data source
Lab + EHR

Research focus and disease area

Illustration person standing
  • Chronic Kidney Disease (CKD): Progressive disease with most patients being at risk of increased cardiovascular disease and death
  • Etiology: most common causes of CKD are diabetes, hypertension, dyslipidemia and inflammation;
As of today, there are no cures for CKD. Available treatments are primarily focusing on slowing the disease progression, managing symptoms and preventing complications – making early detection of CKD in type 2 diabetes patients crucial!
  • Risk factors: weight, age, gender, comorbidities, increased levels of certain laboratory parameters (urine protein, UACR and related creatinine parameters, anemia, hyperuricemia, …)

Intended data insights & knowledge gain

  • Understanding the quantifiable relationship of eGFR & albuminuria measured by UACR to CKD progression, mortality, kidney outcomes, CV events
  • Understanding the mean number of eGFR and UACR tests per year per patient with type II diabetes in Germany per KDIGO heatmap category
  • Determining the accuracy of UACR tests in comparison to dipstick tests
Illustration person sitting
Parameters
  • Longitudinal, large volume and rich healthcare data collected in near-time.
Analysis results
  • Hypertension, cardiovascular events, kidney outcomes
  • eGFR, UACR, creatinine (clearance), urine protein

Our solution & impact

Prognosis of CKD

Based on Honic RWD, we have analysed the patient disease status, visualized as a KDIGO heatmap, displaying risk stratification, monitoring of kidney function and aiding treatment decisions

  • Demonstrate the significance and accuracy of UACR testing in addition to eGFR testing for diagnosis of CKD and its progression
  • Generate robust data to influence change at policy level, aiming to improve early CKD detection for type II diabetes patients at risk of developing CKD
Contact

Schedule a call with our experts

Contact
Nora Sagel
Nora Sagel

CPO & Managing Director

Philipp Hessenberger
Philipp Hessenberger

VP Growth